Chapter IV meaning

Antitrust CMA launches Chapter II investigation into Vifor Pharma regarding the supply of intravenous iron deficiency treatments to the NHS The Commission stated it has opened a Chapter II investigation, under the Competition Act 1998, into Vifor Pharma (Vifor), following concerns of a suspected breach of competition law linked to the supply of intravenous (IV) iron deficiency treatments provided to National Health Service (NHS) patients across the UK...

In this issue: UK antitrust UK competition policy EU antitrust EU mergers EU competition policy EU state aid LexTalk®Competition: a Lexis®Nexis community Daily and weekly news alerts Caselex New and updated content UK antitrust CMA launches Chapter II investigation into Vifor Pharma regarding the supply of intravenous iron deficiency treatments to the NHS The CMA has begun a Chapter II inquiry under the Competition Act 1998 into Vifor Pharma (Vifor) for suspected competition law breaches relating to the supply of intravenous (IV) iron deficiency therapies for NHS patients in the UK. Vifor, a global pharmaceutical company headquartered in Australia, markets Ferinject (ferric caboxymaltose). Pharmacosmos, a family-owned specialist focused on iron deficiency, produces Monofer (ferric derisomaltose). The investigation will consider whether Vifor, whose Ferinject is a leading IV iron treatment in the UK, stifled competition by making misleading claims to healthcare professionals about the safety and effectiveness of Monofer, a rival high-dose IV iron...

In this issue: Data protection and cybersecurity Free movement, immigration and employment Financial services Energy Environment Insurance and reinsurance IP Life sciences Regulatory TMT International trade Daily and weekly news alerts New and updated content Trackers Data protection and cybersecurity Main challenges of EU AI Act-GDPR interplay identified by Member States MLex: EU countries flag potentially clashing legal duties, national governance models to secure regulatory coherence, and a call for clear legal guidance to reduce compliance burdens as the key concerns in aligning the EU AI Act with Regulation (EU) 2016/679 (the EU’s General Data Protection Regulation (EU GDPR)). European governments caution that the regimes’ differing supervisory approaches could produce inconsistent outcomes, which should be prevented through structured co-operation among the competent authorities. See News Analysis: Main challenges of EU AI Act-GDPR interplay identified by Member States. Free movement, immigration and employment European Parliament's Civil Liberties Committee...

ARCHIVED: This retired Practice Note outlines details about the EU General Data Protection Regulation, Regulation (EU) 2016/679 (the GDPR), as it operated in the UK before 11 pm on 31 December 2020. From that point, it is retained strictly for background purposes only and is no longer updated or maintained. For advice on the amendments to UK data protection law introduced by the replacement UK GDPR from that date, consult Practice Notes: The UK General Data Protection Regulation (UK GDPR), The UK General Data Protection Regulation (UK GDPR)—Navigator and Brexit—implications for data protection [Archived]. Brexit On 31 January 2020, the UK left the EU and entered an implementation period up to 11 pm on 31 December 2020, during which it remained bound by EU law for the entire duration of that period. Throughout that time, the EU General Data Protection Regulation, Regulation (EU) 2016/679 (the GDPR), continued to apply in the UK, and the UK was broadly regarded as an EU (and EEA) state for EEA and UK...

Introduction to the MiFID II level 2 and level 3 roadmap The recast Markets in Financial Instruments Directive (Directive 2014/65/EU (MiFID II)) and the Markets in Financial Instruments Regulation (Regulation 600/2014 (MiFIR)) were published in the Official Journal of the EU on 12 June 2014 and entered into force on 2 July 2014. MiFID II and MiFIR significantly reshaped and broadened the regulatory framework that had been established by the Markets in Financial Instruments Directive 2004/39/EC (MiFID I). As amended, the majority of the Directive and the Regulation began to apply on 3 January 2018, and EU Member States had until 3 July 2017 to transpose MiFID II into domestic law. Following the MiFID II/MiFIR review, the Official Journal of the EU on 8 March 2024 set out Regulation (EU) 2024/791 amending MiFIR and Directive (EU) 2024/790 amending MiFID II. Regulation (EU) 2024/791 entered into force on 28 March 2024. Member States are required to transpose the provisions of Directive (EU) 2024/790 into national law by 29 September 2025...

This document is archived and will no longer be updated. For information on EU EMIR, please see Practice Note: EU MiFID II and MiFIR—essentials and the EU Markets in Financial Instruments Directive (MiFID II) and Markets in Financial Instruments Regulation (MiFIR)—timeline. Introduction to the MiFIR level 1 roadmap The recast Markets in Financial Instruments Directive (Directive 2014/65/EU) (MiFID II), together with the Markets in Financial Instruments Regulation (Regulation (EU) 600/2014) (MiFIR), was published in the Official Journal of the European Union on 12 June 2014 and came into force on 2 July 2014. Taken as a package, MiFID II and MiFIR substantially revised and enlarged the regulatory framework first created by the Markets in Financial Instruments Directive (Directive 2004/39/EC) (MiFID I). As amended, the bulk of the new Directive and Regulation applied from 3 January 2018. EU Member States were given until 3 July 2017 to transpose MiFID II into national legislation, while MiFIR has direct effect across Member States...